NIMH CHEMICAL SYNTHESIS PROGRAM

镍氢化学合成项目

• 批准号: 6130692
• 负责人: MARY J TANGA
• 金额: --
• 依托单位: SRI INTERNATIONAL
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-09-30 至 2001-09-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6130692
• 关键词: chemical information system; chemical registry /resource; drug design /synthesis /production; neuropharmacologic agent; psychopharmacologic agent; radiotracer

The purpose of the NIMH Chemical Synthesis and Drug Supply Program is to synthesize and provide essential compounds that are unavailable from commercial sources to stimulate basic and clinical research relevant to mental health in areas such as the molecular pharmacology and signaling of CNS receptors, longitudinal studies to evaluate the molecular, biochemical, and behavioral actions of psychoactive compounds, and functional brain imaging in primates and humans. The objectives of the contract are to synthesize non-GMP compounds and GMP (Good Manufacturing Practices) compounds. Approximately 20% of the chemical syntheses may constitute proprietary compounds. Compounds synthesized under the contract could include, but are not limited to, psychoactive drugs, selective ligands for CNS receptor subtypes, ion channel modulators, signal transduction agents, peptides, small molecules, radiolabeled ligands for autoradiography or neuroimaging, chemicals, probes, and synthetic intermediates. The Contractor will store and maintain new and existing compounds in the NIMH Chemical Synthesis and Drug Supply Program Inventory, maintain an electronic database of compounds with analytical and technical information, distribute compounds to investigators, and maintain an electronic inventory of shipments. It is anticipated that synthesis requests will be submitted from a variety of sources including NIH- funded research programs, biotechnology companies, small pharmaceutical companies, or other sources. It is expected that the chemicals or drugs synthesized and distributed by this program will provide individual investigators with conceptual leads for basic and clinical studies of the neurobiology and treatment of mental disorders.

NIMH化学合成和药物供应计划的目的是 来合成和提供不可用的基本化合物 从商业来源刺激基础和临床研究 与心理健康相关的领域，如分子药理学， 和中枢神经系统受体的信号传导，纵向研究，以评估 精神活性物质的分子、生物化学和行为作用 化合物，以及灵长类动物和人类的功能性脑成像。 的 合同的目标是合成非GMP化合物， GMP（良好生产规范）化合物。大约20%的 化学合成可构成专有化合物。 根据合同合成的化合物可能包括但不包括 仅限于精神活性药物、CNS受体的选择性配体 亚型，离子通道调节剂，信号转导剂， 放射自显影用肽、小分子、放射性标记配体 或神经成像、化学品、探针和合成中间体。的 承包商将在 NIMH化学合成和药物供应计划库存，维护 一个电子数据库的化合物与分析和技术 信息，向调查人员分发化合物，并保持 电子货物清单。预计合成 申请将从各种来源提交，包括NIH- 资助的研究项目，生物技术公司，小型 制药公司或其他来源。预计该 该计划合成和分发的化学品或药物将 为个别调查人员提供基本的概念性线索， 精神分裂症的神经生物学和治疗的临床研究 紊乱